During open-label palopegteriparatide treatment in adults with hypoparathyroidism, median urine calcium declined by 61% to 72% from baseline.
In plain wordsDuring open-label palopegteriparatide treatment, median daily urine calcium declined by 61% to 72% from baseline.
- Peptide
- Palopegteriparatide
- Outcome
- Decrease24-hour urine calcium during extension
- Study
n: not reported in source
- Outcome group
- Kidney function · Kidney and urinary
- Studied dose
- Dose not stated
Measurements
- Urine calcium decline
- 61 to 72%
- during open-label extension
- Baseline median urine calcium
- 381 mg/d
- baseline
- Baseline interquartile range
- 296 to 602 mg/d
- baseline
Source sentences
Median (interquartile range) 24uCa was 381 (296-602) mg/d at baseline and declined by 61% to 72% during OLE.
2 context sentences(design, population, supporting numbers)
This was a post-hoc analysis of the PaTH Forward trial (NCT04009291).
Fifty-nine adults with chronic hypoparathyroidism managed with conventional therapy were enrolled in a randomized, double-blind, placebo-controlled 4-week period followed by an open-label extension (OLE), in which all participants received palopegteriparatide (TransConPTH).